BDRX News and Press, Biodexa Pharmaceuticals PLC-ADR From 03/10/25

2025-03-10 09:28:22 ET DENVER, Colo., Mar 10, 2025 ( 247marketnews.com )- Biodexa Pharmaceuticals (NASDAQ: BDRX ) announced a successful Type C meeting with the U.S. Food and Drug Administration (FDA), paving the way for its registrational Phase 3 study of eRapa in familial adenomat...

March 10, 2025 Biodexa Announces Successful Outcome of a Type C Meeting with FDA Regarding the Phase 3 Program for eRapa in FAP Clears the way to finalize Phase 3 protocol and recruit sites for U.S. Phase 3 substantially funded by $17.0 million CPRIT grant and $8.5 mil...

March 6, 2025 Biodexa Announces Appointment of Precision for Medicine LLC as CRO for European Component of Phase 3 Study of eRapa in FAP Biodexa is finalizing plans to initiate an international Phase 3 registrational study of eRapa in Familial Adenomatous Polyposis (FAP) next ...

February 24, 2025 Biodexa Announces Allowance of U.S. Patent Covering Oral Rapamycin Nanoparticle Preparations (“eRapa”) and Use Biodexa plans to initiate a Phase 3 registrational study of eRapa in Familial Adenomatous Polyposis (FAP) next quarter Bio...

CARDIFF, UK / ACCESS Newswire / February 12, 2025 / Biodexa Pharmaceuticals PLC. (NASDAQ:BDRX), a clinical-stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, received Fast Track status from the U.S. Food and ...

2025-02-10 09:57:31 ET More on Biodexa Pharmaceuticals Seeking Alpha’s Quant Rating on Biodexa Pharmaceuticals Historical earnings data for Biodexa Pharmaceuticals Financial information for Biodexa Pharmaceuticals Read the full article on Seeking Alp...

2025-02-10 09:51:58 ET DENVER, Colo., Feb 10, 2025 ( 247marketnews.com )- Biodexa Pharmaceuticals (NASDAQ: BDRX ) reported that the US Food and Drug Administration (“FDA”) granted Fast Track designation for eRapa. eRapa is Biodexa’s proprietary encapsulated form...

February 10, 2025 Biodexa Receives US FDA Fast Track Designation for eRapa in Familial Adenomatous Polyposis Underscores unmet need for a therapeutic alternative with the potential to delay or prevent surgical removal of the colon and/or rectum Biodexa Pharmaceuticals PLC ...

2025-01-22 08:43:46 ET More on Biodexa Pharmaceuticals Seeking Alpha’s Quant Rating on Biodexa Pharmaceuticals Historical earnings data for Biodexa Pharmaceuticals Financial information for Biodexa Pharmaceuticals Read the full article on Seeking Alp...

January 22, 2025 Biodexa Strengthens Management Team Appointment of Dr Gary A. Shangold as Chief Medical Officer Biodexa Pharmaceuticals PLC (“Biodexa” or “the Company”), (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeli...